BOSTON, Sept. 19, 2024 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing therapeutics for significant unmet medical needs, today announced that research involving its leading drug candidate, ProLectin-M, was published in a peer-reviewed medical journal by the European Society of Medicine.
The publication examines the role of galectin-3 in viral attachment and entry and describes research using advanced Nuclear Magnetic Resonance (NMR) spectroscopy to investigate how Bioxytran's carbohydrate-based drug candidate interacts with viral structures.
The findings support further investigation of galectins as potential targets for antiviral drug development and Bioxytran's broader research into carbohydrate-based approaches to viral diseases.
The peer-reviewed article investigates how galectin-3 may contribute to viral attachment to human cells.
According to the research, galectin-3 can interact with the ACE2 receptor and may contribute to the process by which viruses attach to and enter host cells. The study used Nuclear Magnetic Resonance (NMR) spectroscopy to examine these molecular interactions and the mechanism of action associated with Bioxytran's drug candidate.
The research provides additional scientific support for investigating galectin-mediated pathways as potential targets for antiviral drug development.
ProLectin-M is Bioxytran's leading investigational antiviral drug candidate and is based on the Company's proprietary complex carbohydrate chemistry.
The Company's research focuses on the interaction between carbohydrates and galectin-related structures involved in viral attachment. By investigating these interactions, Bioxytran is exploring whether carbohydrate-based molecules can interfere with viral entry before the virus establishes infection within a host cell.
The peer-reviewed research reported that the Company's approach can block interactions associated with viral attachment and investigated the resulting effect on viral entry.
As an investigational drug candidate, additional research is required to establish the safety and efficacy of ProLectin-M across different viral diseases and patient populations.
A central component of the study was the use of Nuclear Magnetic Resonance spectroscopy to examine the molecular interactions underlying the proposed mechanism.
The research investigated how galectin-related structures interact with viral proteins and host-cell receptors. These molecular-level observations provide a basis for understanding how Bioxytran's carbohydrate-based compounds may interfere with viral attachment.
The findings build on Bioxytran's broader strategy of using scientific and computational tools to investigate druggable molecular targets and develop rationally designed carbohydrate structures.
One of the potential implications of targeting galectin-related structures is that these regions may be more conserved than other viral components that can change through mutation.
The study examined galectin-related structures associated with viral spike proteins and their role in viral attachment. Bioxytran is investigating whether targeting such conserved structures could provide opportunities for developing antiviral therapies with activity across multiple viral families.
Previous company research has examined Bioxytran's carbohydrate-based molecules against viruses including SARS-CoV-2, RSV, and H1N1.
However, the extent to which the Company's carbohydrate structures may neutralize other viruses remains unknown and requires additional research and validation.
The peer-reviewed publication adds to Bioxytran's ongoing research into galectin antagonists and their potential role in antiviral development.
The Company has previously reported results from double-blind, placebo-controlled clinical studies involving its antiviral drug candidates and research evaluating viral load and symptom-related outcomes.
These findings form part of the Company's broader development program, while additional clinical research is necessary to independently establish the safety and efficacy of ProLectin-M and determine its potential therapeutic applications.
The identification of galectin-related structures as potential targets could provide another avenue for antiviral drug development.
Traditional antiviral approaches may focus on viral enzymes or replication machinery. Bioxytran's research instead investigates viral attachment and host-pathogen interactions, with the objective of interfering with infection at an earlier stage.
"This discovery might be one of the most significant advancements in virology," said Dr. David Platt, CEO of Bioxytran. "In our first case study to make a SARS-CoV-2 antiviral drug, it appears we have on our hands the first truly broad-spectrum antiviral that may operate across different families of viruses."
"We believe we have discovered a reproducible method that could potentially be used to create many antiviral drugs that could potentially quickly fight off new viruses, even those that mutate rapidly. We believe our approach represents a new era in antiviral drug development. With the help of advanced technology and Artificial Intelligence (AI), it is now possible to design antiviral drugs that could potentially neutralize any virus. This discovery could change the way we treat viral diseases and even chronic illnesses like cancer. We believe major advancements in virology with this new tech will be measured in months instead of years and decades as has been the case in the past."
Dr. Kevin Mayo, Professor of the University of Minnesota, commented on the potential significance of the Company's approach.
"Using this new platform technology could revolutionize how we create new antiviral treatments," said Dr. Mayo. "Traditional methods of developing antivirals and vaccines are not precise and involve a lot of trial and error."
"Our results show we can neutralize viruses without the help of the immune system making our system incredibly reliable. This breakthrough opens a new chapter in fighting viral diseases, providing hope for treating not only SARS-CoV-2 but other highly pathogenic and contagious viruses influenced by galectins. This may be the crown jewel of virology and a few more tests on other viruses could prove it."
The potential application of broad-spectrum antiviral technologies exists within large and growing global markets.
According to market figures cited in the original release, the global antiviral drugs market was valued at $72.84 billion, while the global vaccine market was valued at $74.12 billion in 2024, representing a combined market opportunity of approximately $147 billion.
The antiviral market continues to be driven by the prevalence of viral diseases including HIV, hepatitis, and influenza, as well as continued investment in antiviral drug development. The release also identified increasing demand for broad-spectrum antiviral approaches that could potentially be deployed against emerging viral threats.
The vaccine market has similarly experienced continued technological development, including advances in mRNA technology, protein-based vaccines, and other vaccine-delivery technologies.
The research reflects Bioxytran's broader focus on complex carbohydrate drug design.
The Company uses artificial intelligence software alongside Nuclear Magnetic Resonance imaging to investigate druggable targets such as the galectin fold and support the development of rationally designed carbohydrate structures.
Bioxytran's platform is being investigated across multiple areas of significant unmet medical need, including virology, degenerative disease, hypoxia, and tissue injury.
The peer-reviewed publication provides additional scientific support for Bioxytran's investigation of galectins as potential antiviral targets.
The Company will continue evaluating ProLectin-M and related carbohydrate-based molecules through additional laboratory and clinical research. Further studies will be required to determine whether the observed molecular mechanisms translate into clinically meaningful antiviral activity across different viruses.
Bioxytran is also continuing to investigate whether its carbohydrate-based platform can be applied to additional viral and disease targets.
Bioxytran, Inc. is a clinical-stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets Nuclear Magnetic Resonance imaging of druggable targets such as the galectin fold to support rational drug design.
The Company's leading drug candidates have been evaluated through in vitro testing for their ability to neutralize viruses. Peer-reviewed research involving the galectin fold located on the spike proteins of viruses including COVID-19, RSV, and H1N1 has demonstrated a conserved region on the spike where Bioxytran's molecules achieve virus neutralization.
The extent of the carbohydrate structures' ability to neutralize untested viruses remains unknown and requires additional research.
Applications of the Company's platform technology extend to significant unmet medical needs in virology, degenerative disease, and hypoxia. Bioxytran's leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. The Company is also advancing development programs for pulmonary fibrosis and stroke.
This news release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning the potential applications of ProLectin-M, galectin antagonists, carbohydrate-based therapeutics, broad-spectrum antiviral activity, future research, clinical development, market opportunities, and the potential therapeutic applications of Bioxytran's technology. These statements are based on current expectations and are subject to significant risks, assumptions, and uncertainties that could cause actual results to differ materially from those expressed or implied.
Factors that may affect future results include preclinical and clinical findings, regulatory decisions, development timelines, funding availability, manufacturing considerations, strategic partnerships, market conditions, and other risks described in Bioxytran's filings with the U.S. Securities and Exchange Commission. The investigational technologies described in this release have not been established as safe or effective for the treatment or prevention of viral diseases unless specifically approved for such use. Bioxytran undertakes no obligation to update forward-looking statements except as required by applicable law.
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
